Skip to main content

Table 5 Clinical adverse experiences for which the 95% confidence intervals around the difference in incidence rate exclude 0

From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

Adverse Experience Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference in Sitagliptin
and Non-Exposed,
% (95% CI)*
Sitagliptin > Non-exposed
Atrial fibrillation 18 (0.5) 5 (0.2) 0.3 (0.0, 0.7)
Asthenia 19 (0.6) 6 (0.2) 0.3 (0.0, 0.7)
Chest discomfort 9 (0.3) 1 (0.0) 0.2 (0.0, 0.5)
Tooth abscess 27 (0.8) 10 (0.4) 0.4 (0.0, 0.8)
Osteoarthritis 58 (1.7) 24 (0.9) 0.8 (0.2, 1.4)
Acne 7 (0.2) 0 (0) 0.2 (0.0, 0.4)
Dermatitis Contact 24 (0.7) 7 (0.3) 0.4 (0.1, 0.8)
Non-exposed > Sitagliptin
Bradycardia 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Goiter 1 (0.0) 6 (0.2) -0.2 (-0.5, -0.0)
Change in bowel habit 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Blood glucose decreased 13 (0.4) 28 (1.0) -0.6 (-1.1, -0.2)
Blood glucose increased 42 (1.2) 51 (1.9) -0.6 (-1.3, -0.0)
Weight increased 12 (0.4) 20 (0.7) -0.4 (-0.8, -0.0)
Hypoglycemia 117 (3.4) 296 (10.9) -7.4 (-8.8, -6.1)
Sinus headache 3 (0.1) 12 (0.4) -0.4 (-0.7, -0.1)
Prostatitis 3 (0.1) 9 (0.3) -0.2 (-0.5, -0.0)
Balanitis 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Hyperkeratosis 0 (0) 8 (0.3) -0.3 (-0.6, -0.1)
  1. CI = confidence interval
  2. *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
  3. When atrial fibrillation and atrial flutter were combined, the incidence rates were 0.5% and 0.3% for the sitagliptin and non-exposed groups, respectively (between-group difference [95% CI] = 0.3 [-0.1, 0.6]).
  4. When tooth abscess and tooth infection were combined, the incidence rates were 1.3% and 0.9% for the sitagliptin and non-exposed groups, respectively (between-group difference [95% CI] = 0.4 [-0.1, 1.0]).